Yahoo finance “CASI Pharmaceuticals Inc (CASI), a biopharmaceutical company dedicated to developing high-quality products and therapeutics to the global health market, announced earlier this month that it had received National Medical Products Administration approval of Melphalan Hydrochloride For Injection.
CASI Pharmaceuticals Executive Chairman Wei-Wu He, Ph.D., commented, ''NMPA approval of Melphalan Hydrochloride For Injection (EVOMELA®) is encouraging news for patients in China with multiple myeloma as there is no commercially available melphalan formulation in the country. EVOMELA's approval, therefore, addresses a significant unmet medical need. In addition, EVOMELA®‘s proprietary formulation of melphalan, a first-line therapy for multiple myeloma patients, offers considerable clinical advantages as it does not contain propylene glycol, which may cause side effects, it has long stability when reconstituted for infusion, and is the only intravenous melphalan product approved for use in the high-dose conditioning indication in pre-transplant therapy.''
This is one I feel has great growth potential. Good thing as well at there is more institutional investors than general public shows investors have a lot of confidence in the company.
Again, I’m not giving financial advice and you should check things out for yourself. Just sharing my thoughts
CASI Pharmaceuticals Executive Chairman Wei-Wu He, Ph.D., commented, ''NMPA approval of Melphalan Hydrochloride For Injection (EVOMELA®) is encouraging news for patients in China with multiple myeloma as there is no commercially available melphalan formulation in the country. EVOMELA's approval, therefore, addresses a significant unmet medical need. In addition, EVOMELA®‘s proprietary formulation of melphalan, a first-line therapy for multiple myeloma patients, offers considerable clinical advantages as it does not contain propylene glycol, which may cause side effects, it has long stability when reconstituted for infusion, and is the only intravenous melphalan product approved for use in the high-dose conditioning indication in pre-transplant therapy.''
This is one I feel has great growth potential. Good thing as well at there is more institutional investors than general public shows investors have a lot of confidence in the company.
Again, I’m not giving financial advice and you should check things out for yourself. Just sharing my thoughts
Lord MEDZ